Apple (NASDAQ:AAPL), maker of smartphones, computers, tablets, and other services, closed Monday at $301.54, down 1.89%. The stock initially moved as high as about $317 per share as investors reacted to WWDC 2026 disclosures around a next-generation AI-powered Siri, the new “Appl
Apple (NASDAQ:AAPL), maker of smartphones, computers, tablets, and other services, closed Monday at $301.54, down 1.89%. The stock initially moved as high as about $317 per share as investors reacted to WWDC 2026 disclosures around a next-generation AI-powered Siri, the new “Appl
SpaceX disclosed a cloud service agreement with Google covering about 110,000 NVIDIA GPUs at its Memphis data centers, adding to a separate $1.25 billion monthly Anthropic deal.
SpaceX disclosed a cloud service agreement with Google covering about 110,000 NVIDIA GPUs at its Memphis data centers, adding to a separate $1.25 billion monthly Anthropic deal.
Apple's (AAPL) annual Worldwide Developers Conference (WWDC) kicks off on Monday at the iPhone maker's headquarters, where the company unveiled its new AI-powered Siri (or Siri AI). Yahoo Finance Tech Editor Dan Howley reports live from Cupertino, CA, to share the biggest takeaways from the 2026 WWDC. This is Tim Cook's final WWDC as Apple CEO before he steps down this September, transitioning int...
Apple's (AAPL) annual Worldwide Developers Conference (WWDC) kicks off on Monday at the iPhone maker's headquarters, where the company unveiled its new AI-powered Siri (or Siri AI). Yahoo Finance Tech Editor Dan Howley reports live from Cupertino, CA, to share the biggest takeaways from the 2026 WWDC. This is Tim Cook's final WWDC as Apple CEO before he steps down this September, transitioning into an executive chairman role.
tigerstrawberry/iStock via Getty Images Emergent BioSolutions Inc. ( EBS ) was founded in 1998 and is based in Gaithersburg, MD. It describes itself as ‘a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats.’ Emergent has 11 products, with its business spread across three d...
tigerstrawberry/iStock via Getty Images Emergent BioSolutions Inc. ( EBS ) was founded in 1998 and is based in Gaithersburg, MD. It describes itself as ‘a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats.’ Emergent has 11 products, with its business spread across three distinct segments: Commercial products, consisting of Narcan 4mg nasal spray and Kloxxado 8mg nasal spray to treat opioid (esp. fentanyl) overdosing; Medical counter-measures (MCM) products, consisting of vaccines and treatments for Anthrax and Smallpox, predominantly, alongside also Mpox, Botulism, and Ebola; Bioservices offerings. The revenue split across all three is outlined below for Q1 2026 revenues. Data from 10-Q Comparing Q1 2025 to Q1 2026, total revenue fell from $222.2 million to $156.1 million. All three segments experienced declines in revenue y/y. The fall in MCM revenue was the most dramatic in terms of total dollar amounts. Data from 10-Q With the stock down over 40% from a recent high and 94% from its all-time high, investors may be inclined to pick up shares in hopes of a turnaround. I was bearish in my last article , calling it a “value trap,” but the stock has rebounded by 55% since then. Seeking Alpha In this article, I’ll offer my thoughts on the price action and discuss their two main revenue drivers: Naloxone and MCM. I’ll discuss the former first, as it was the strongest part of their business, by which I mean it declined by the lowest percentage compared to the others. The Naloxone Business Segment As a reminder, Narcan is the well-known brand name of the naloxone nasal spray that provides an emergency life-saving response to opioid overdose, not just for fentanyl but also for heroin, oxycodone (OxyContin), hydrocodone (Vicodin), codeine, and morphine. Emergent acquired the rights to Narcan nasal spray in 2018, and it received FDA approval to be su...
Mama's Creations, Inc. (MAMA) delivered earnings and revenue surprises of +66.67% and +1.87%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Mama's Creations, Inc. (MAMA) delivered earnings and revenue surprises of +66.67% and +1.87%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Intel (NASDAQ:INTC), which designs and manufactures semiconductor products, including CPUs and GPUs, closed Monday at $110.27, up 11.19%. The stock moved higher as reports highlighted a major Google AI chip order and potential foundry roles with Google and Nvidia. Investors are w
Intel (NASDAQ:INTC), which designs and manufactures semiconductor products, including CPUs and GPUs, closed Monday at $110.27, up 11.19%. The stock moved higher as reports highlighted a major Google AI chip order and potential foundry roles with Google and Nvidia. Investors are w
S&P 500 (SNPINDEX:^GSPC) rose 0.30% to 7,405.73 and the Nasdaq Composite (NASDAQINDEX:^IXIC) climbed 0.86% to 25,929.66 as tech stocks began to recover from Friday’s rout. The Dow Jones Industrial Average (DJINDICES:^DJI) slipped 0.16% to 50,786.01 as cyclicals lagged.
S&P 500 (SNPINDEX:^GSPC) rose 0.30% to 7,405.73 and the Nasdaq Composite (NASDAQINDEX:^IXIC) climbed 0.86% to 25,929.66 as tech stocks began to recover from Friday’s rout. The Dow Jones Industrial Average (DJINDICES:^DJI) slipped 0.16% to 50,786.01 as cyclicals lagged.
For the past several years, the market has associated Eli Lilly (NYSE: LLY) with one thing: obesity. Its blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro have transformed the company, helping drive annual revenue from $34.1 billion in 2023 to more than $65.2 billion in 2025. But it would be foolish to ignore the elephant in the room: What's next after GLP-1 and obesity treatme...
For the past several years, the market has associated Eli Lilly (NYSE: LLY) with one thing: obesity. Its blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro have transformed the company, helping drive annual revenue from $34.1 billion in 2023 to more than $65.2 billion in 2025. But it would be foolish to ignore the elephant in the room: What's next after GLP-1 and obesity treatments? Lilly may have just provided part of the answer. Image source: Getty Images. Continue reading
Never miss an episode. Follow The Big Take daily podcast today. The field for the 2026 US midterm elections is coming into focus, with key primaries this week in Maine and South Carolina, as well as bellwether state elections in California. On today’s Big Take podcast, hosts Sarah Holder and David Gura check in with political correspondent Nancy Cook and California reporter Eliyahu Kamisher about ...
Never miss an episode. Follow The Big Take daily podcast today. The field for the 2026 US midterm elections is coming into focus, with key primaries this week in Maine and South Carolina, as well as bellwether state elections in California. On today’s Big Take podcast, hosts Sarah Holder and David Gura check in with political correspondent Nancy Cook and California reporter Eliyahu Kamisher about what this week’s results — and the next five months — mean for midterm elections with the potential to profoundly shape US politics. We have a special Bloomberg subscription offer for podcast listeners at Bloomberg.com/podcastoffer. Listen and follow The Big Take on Apple Podcasts , Spotify or wherever you get your podcasts. Terminal clients: Visit NSUB to subscribe. This episode was produced by: Julia Press; Editors: Jeffrey Grocott; Fact-checker: Laura Newcombe; Sound Design/Engineer: Alex Sugiura; Senior Producer: Naomi Shavin; Senior Editor: Elisabeth Ponsot; Deputy Executive Producer: Julia Weaver; Executive Producer: Nicole Beemsterboer.